Health & bio

FDA Approves Interchangeable Insulin Glargine 'Langlara' on April 29

Lantus biosimilar approved for diabetes treatment with interchangeable designation.

Primary sources · 1
Drugs.com
← View the full 2026-05-02 (Sat) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →